{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:38:49Z","timestamp":1762843129869,"version":"build-2065373602"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T00:00:00Z","timestamp":1690416000000},"content-version":"vor","delay-in-days":207,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2023]]},"DOI":"10.1016\/j.ctarc.2023.100750","type":"journal-article","created":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T21:44:48Z","timestamp":1690580688000},"page":"100750","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Non-coding RNAs, cancer treatment and cardiotoxicity: A triad of new hope"],"prefix":"10.1016","volume":"36","author":[{"given":"Rishabh","family":"Mittal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarath","family":"Krishnan M P","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahul","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ananyan","family":"Sampath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bela","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ctarc.2023.100750_bib0001","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jacc.2022.04.042","article-title":"Cardiovascular disease risk among cancer survivors: the atherosclerosis risk in communities (ARIC) study","volume":"80","author":"Florido","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ctarc.2023.100750_bib0002","unstructured":"The top 10 causes of death. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/the-top-10-causes-of-death (accessed 2023-04-27)."},{"key":"10.1016\/j.ctarc.2023.100750_bib0003","unstructured":"Cancer. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cancer (accessed 2023-04-27)."},{"issue":"7","key":"10.1016\/j.ctarc.2023.100750_bib0004","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/s41416-019-0721-1","article-title":"Cancer as a disease of old age: changing mutational and microenvironmental landscapes","volume":"122","author":"Laconi","year":"2020","journal-title":"Br. J. Cancer"},{"issue":"9","key":"10.1016\/j.ctarc.2023.100750_bib0005","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1177\/2047487320943002","article-title":"Assessing cardiovascular risk in cancer patients: opportunities and challenges","volume":"28","author":"Guha","year":"2021","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"11","key":"10.1016\/j.ctarc.2023.100750_bib0006","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1161\/CIRCULATIONAHA.117.024671","article-title":"Exercise therapy and cardiovascular toxicity in cancer","volume":"137","author":"Scott","year":"2018","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.ctarc.2023.100750_bib0007","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s12265-020-10042-3","article-title":"The role of biomarkers in cardio-oncology","volume":"13","author":"Ananthan","year":"2020","journal-title":"J. Cardiovasc. Transl. Res."},{"issue":"4","key":"10.1016\/j.ctarc.2023.100750_bib0008","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/ehf2.12493","article-title":"Heart failure from cancer therapy: can we prevent it?","volume":"6","author":"Totzeck","year":"2019","journal-title":"ESC Heart Fail."},{"issue":"2","key":"10.1016\/j.ctarc.2023.100750_bib0009","first-page":"60","article-title":"MicroRNA and cardiovascular diseases","volume":"37","author":"\u00c7akmak","year":"2020","journal-title":"Balkan Med. J."},{"issue":"1","key":"10.1016\/j.ctarc.2023.100750_bib0010","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13578-022-00757-y","article-title":"Long non-coding RNAs and microRNAs as crucial regulators in cardio-oncology","volume":"12","author":"Nukala","year":"2022","journal-title":"Cell Biosci."},{"issue":"41","key":"10.1016\/j.ctarc.2023.100750_bib0011","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur. Heart J."},{"issue":"2","key":"10.1016\/j.ctarc.2023.100750_bib0012","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1200\/JCO.1996.14.2.328","article-title":"Dexrazoxane for protection against cardiotoxic effects of anthracyclines in children","volume":"14","author":"Lipshultz","year":"1996","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.ctarc.2023.100750_bib0013","first-page":"39","article-title":"Epigenetic regulation of vascular diseases","author":"A","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"16","key":"10.1016\/j.ctarc.2023.100750_bib0014","doi-asserted-by":"crossref","first-page":"9353","DOI":"10.3390\/ijms23169353","article-title":"Using NcRNAs as tools in cancer diagnosis and treatment-the way towards personalized medicine to improve patients\u2019 health","volume":"23","author":"Piergentili","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.ctarc.2023.100750_bib0015","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1159\/000487044","article-title":"Attenuation of microRNA-495 derepressed PTEN to effectively protect rat cardiomyocytes from hypertrophy","volume":"139","author":"Fu","year":"2018","journal-title":"Cardiology"},{"issue":"9","key":"10.1016\/j.ctarc.2023.100750_bib0016","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1161\/CIRCRESAHA.112.300682","article-title":"MicroRNA-22 regulates cardiac hypertrophy and remodeling in response to stress","volume":"112","author":"Huang","year":"2013","journal-title":"Circ. Res."},{"issue":"12","key":"10.1016\/j.ctarc.2023.100750_bib0017","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.7150\/thno.15007","article-title":"Crucial role of MiR-433 in regulating cardiac fibrosis","volume":"6","author":"Tao","year":"2016","journal-title":"Theranostics"},{"issue":"4","key":"10.1016\/j.ctarc.2023.100750_bib0018","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1002\/med.21790","article-title":"Emerging roles of microRNA-208a in cardiology and reverse cardio-oncology","volume":"41","author":"Wang","year":"2021","journal-title":"Med. Res. Rev."},{"issue":"5","key":"10.1016\/j.ctarc.2023.100750_bib0019","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1248\/bpb.29.903","article-title":"Let-7 microRNA functions as a potential growth suppressor in human colon cancer cells","volume":"29","author":"Akao","year":"2006","journal-title":"Biol. Pharm. Bull."},{"issue":"11","key":"10.1016\/j.ctarc.2023.100750_bib0020","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ejhf.1920","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur. J. Heart Fail."},{"issue":"2","key":"10.1016\/j.ctarc.2023.100750_bib0021","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1053\/j.seminoncol.2013.01.011","article-title":"Cardio-oncology for the 21st century: introduction","volume":"40","author":"Schwartz","year":"2013","journal-title":"Semin Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2023.100750_bib0022","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.taap.2011.08.024","article-title":"P21(WAF1\/Cip1\/Sdi1) knockout mice respond to doxorubicin with reduced cardiotoxicity","volume":"257","author":"Terrand","year":"2011","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"7","key":"10.1016\/j.ctarc.2023.100750_bib0023","doi-asserted-by":"crossref","first-page":"e22801","DOI":"10.1371\/journal.pone.0022801","article-title":"Cardiomyocyte specific ablation of P53 is not sufficient to block doxorubicin induced cardiac fibrosis and associated cytoskeletal changes","volume":"6","author":"Feridooni","year":"2011","journal-title":"PLoS ONE"},{"issue":"9","key":"10.1016\/j.ctarc.2023.100750_bib0024","doi-asserted-by":"crossref","first-page":"8290","DOI":"10.1074\/jbc.M308033200","article-title":"Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes","volume":"279","author":"Lim","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.ctarc.2023.100750_bib0025","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.yjmcc.2011.01.018","article-title":"Proteomic insights into chronic anthracycline cardiotoxicity","volume":"50","author":"St\u011brba","year":"2011","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"36","key":"10.1016\/j.ctarc.2023.100750_bib0026","doi-asserted-by":"crossref","first-page":"22800","DOI":"10.1074\/jbc.272.36.22800","article-title":"A novel cardiac-restricted target for doxorubicin. CARP, a nuclear modulator of gene expression in cardiac progenitor cells and cardiomyocytes","volume":"272","author":"Jeyaseelan","year":"1997","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.ctarc.2023.100750_bib0027","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/cvr\/cvq361","article-title":"Mechanism of anthracycline-mediated down-regulation of GATA4 in the heart","volume":"90","author":"Park","year":"2011","journal-title":"Cardiovasc. Res."},{"issue":"6","key":"10.1016\/j.ctarc.2023.100750_bib0028","first-page":"2200","article-title":"Active efflux of daunorubicin and adriamycin in sensitive and resistant sublines of P388 leukemia","volume":"39","author":"Inaba","year":"1979","journal-title":"Cancer Res."},{"issue":"15","key":"10.1016\/j.ctarc.2023.100750_bib0029","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.3390\/jcm10153313","article-title":"N-terminal pro brain natriuretic peptide, SST2, and galectin-3 levels in breast cancer survivors","volume":"10","author":"Patel","year":"2021","journal-title":"J. Clin. Med."},{"issue":"11","key":"10.1016\/j.ctarc.2023.100750_bib0030","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2023.100750_bib0031","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.736854","article-title":"Risk factors for anthracycline-induced cardiotoxicity","volume":"8","author":"Qiu","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"issue":"11","key":"10.1016\/j.ctarc.2023.100750_bib0032","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/cncr.11407","article-title":"Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials","volume":"97","author":"Swain","year":"2003","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ctarc.2023.100750_bib0033","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/jnci\/djp440","article-title":"Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention","volume":"102","author":"Albini","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ctarc.2023.100750_bib0034","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.847012","article-title":"Cardiotoxicity of anticancer drugs: molecular mechanisms and strategies for cardioprotection","volume":"9","author":"Morelli","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"issue":"1","key":"10.1016\/j.ctarc.2023.100750_bib0035","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMra043186","article-title":"Trastuzumab-mechanism of action and use in clinical practice","volume":"357","author":"Hudis","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ctarc.2023.100750_bib0036","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11864-020-0719-1","article-title":"Cardiotoxicities of 5-fluorouracil and other fluoropyrimidines","volume":"21","author":"Shiga","year":"2020","journal-title":"Curr. Treat Options Oncol."},{"issue":"9","key":"10.1016\/j.ctarc.2023.100750_bib0037","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1200\/JCO.1991.9.9.1704","article-title":"Cardiac disturbances during the administration of taxol","volume":"9","author":"Rowinsky","year":"1991","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2023.100750_bib0038","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.pharmthera.2018.04.009","article-title":"Anticancer drug-induced cardiac rhythm disorders: current knowledge and basic underlying mechanisms","volume":"189","author":"Alexandre","year":"2018","journal-title":"Pharmacol. Ther."},{"issue":"8","key":"10.1016\/j.ctarc.2023.100750_bib0039","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/nm1446","article-title":"Cardiotoxicity of the cancer therapeutic agent imatinib mesylate","volume":"12","author":"Kerkel\u00e4","year":"2006","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.ctarc.2023.100750_bib0040","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3390\/ijms23010441","article-title":"Cancer therapy-induced cardiotoxicity-A metabolic perspective on pathogenesis, diagnosis and therapy","volume":"23","author":"Choksey","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ctarc.2023.100750_bib0041","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2147\/CMAR.S77400","article-title":"Cancer therapy and cardiovascular risk: focus on bevacizumab","volume":"7","author":"Economopoulou","year":"2015","journal-title":"Cancer Manag. Res."},{"issue":"7","key":"10.1016\/j.ctarc.2023.100750_bib0042","doi-asserted-by":"crossref","first-page":"621","DOI":"10.2165\/00002018-200629070-00007","article-title":"Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk","volume":"29","author":"Motsko","year":"2006","journal-title":"Drug-Safety"},{"issue":"7","key":"10.1016\/j.ctarc.2023.100750_bib0043","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1161\/CIRCULATIONAHA.118.035516","article-title":"Synergistic opportunities in the interplay between cancer screening and cardiovascular disease risk assessment: together we are stronger","volume":"138","author":"Handy","year":"2018","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.ctarc.2023.100750_bib0044","doi-asserted-by":"crossref","first-page":"H459","DOI":"10.1152\/ajpheart.00401.2018","article-title":"Early myocardial changes induced by doxorubicin in the nonfailing dilated ventricle","volume":"316","author":"Rodrigues","year":"2019","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"11","key":"10.1016\/j.ctarc.2023.100750_bib0045","first-page":"116","article-title":"Cardiac dysfunction in cancer patients: beyond direct cardiomyocyte damage of anticancer drugs: novel cardio-oncology insights from the joint 2019 meeting of the ESC working groups of myocardial function and cellular biology of the heart","author":"Cg","year":"2020","journal-title":"Cardiovasc. Res."},{"issue":"8","key":"10.1016\/j.ctarc.2023.100750_bib0046","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.3390\/nu12082317","article-title":"Vanillin prevents doxorubicin-induced apoptosis and oxidative stress in rat H9c2 cardiomyocytes","volume":"12","author":"Sirangelo","year":"2020","journal-title":"Nutrients"},{"issue":"11","key":"10.1016\/j.ctarc.2023.100750_bib0047","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1161\/CIRCRESAHA.117.311082","article-title":"Autophagy and mitophagy in cardiovascular disease","volume":"120","author":"Bravo-San Pedro","year":"2017","journal-title":"Circ. Res."},{"key":"10.1016\/j.ctarc.2023.100750_bib0048","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.tox.2016.09.011","article-title":"Basal autophagy protects cardiomyocytes from doxorubicin-induced toxicity","volume":"370","author":"Pizarro","year":"2016","journal-title":"Toxicology"},{"issue":"1","key":"10.1016\/j.ctarc.2023.100750_bib0049","doi-asserted-by":"crossref","first-page":"H160","DOI":"10.1152\/ajpheart.00418.2018","article-title":"Noncoding RNAs: potential regulators in cardioncology","volume":"316","author":"Chatterjee","year":"2019","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"22","key":"10.1016\/j.ctarc.2023.100750_bib0050","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.3390\/cells11223551","article-title":"MicroRNAs in cancer and cardiovascular disease","volume":"11","author":"Ilieva","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.ctarc.2023.100750_bib0051","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112118","article-title":"Mesenchymal stem cell-derived exosome microRNA as therapy for cardiac ischemic injury","volume":"143","author":"Nasser","year":"2021","journal-title":"Biomed. Pharmacother."},{"issue":"5","key":"10.1016\/j.ctarc.2023.100750_bib0052","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s40256-018-0286-z","article-title":"Acute coronary syndrome in cancer patients","volume":"18","author":"Yetis Sayin","year":"2018","journal-title":"Am. J. Cardiovasc. Drugs"},{"issue":"11","key":"10.1016\/j.ctarc.2023.100750_bib0053","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.2217\/bmm.15.50","article-title":"Development and regulatory application of microRNA biomarkers","volume":"9","author":"Krauskopf","year":"2015","journal-title":"Biomark. Med."},{"issue":"5","key":"10.1016\/j.ctarc.2023.100750_bib0054","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.cell.2019.10.017","article-title":"The role of non-coding RNAs in oncology","volume":"179","author":"Slack","year":"2019","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.ctarc.2023.100750_bib0055","doi-asserted-by":"crossref","first-page":"6994","DOI":"10.18632\/oncotarget.14355","article-title":"Circulating MiR-1 as a potential biomarker of doxorubicin-induced cardiotoxicity in breast cancer patients","volume":"8","author":"Rigaud","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.ctarc.2023.100750_bib0056","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ncrna.2022.01.001","article-title":"Exosomal RNAs in diagnosis and therapies","volume":"7","author":"Narang","year":"2022","journal-title":"Noncoding RNA Res."},{"issue":"3","key":"10.1016\/j.ctarc.2023.100750_bib0057","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s12010-021-03695-6","article-title":"Copeptin, MiRNA-208, and MiRNA-499 as new biomarkers for early detection of acute coronary syndrome","volume":"194","author":"Gaber","year":"2022","journal-title":"Appl. Biochem. Biotechnol."},{"issue":"3","key":"10.1016\/j.ctarc.2023.100750_bib0058","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.suronc.2018.06.003","article-title":"Role of non-coding RNAs in cardiotoxicity of chemotherapy","volume":"27","author":"Song","year":"2018","journal-title":"Surg. Oncol."},{"key":"10.1016\/j.ctarc.2023.100750_bib0059","doi-asserted-by":"crossref","first-page":"42916","DOI":"10.1038\/srep42916","article-title":"Circulating MiR-155, MiR-145 and Let-7c as diagnostic biomarkers of the coronary artery disease","volume":"7","author":"Faccini","year":"2017","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.ctarc.2023.100750_bib0060","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1002\/jcla.23332","article-title":"Diagnostic and prognostic value of circulating MiRNA-499 and MiRNA-22 in acute myocardial infarction","volume":"34","author":"Wang","year":"2020","journal-title":"J. Clin. Lab. Anal."},{"issue":"18","key":"10.1016\/j.ctarc.2023.100750_bib0061","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ctarc.2023.100750_bib0062","doi-asserted-by":"crossref","first-page":"121","DOI":"10.4143\/crt.2008.40.3.121","article-title":"Clinical correlation between brain natriutetic peptide and anthracyclin-induced cardiac toxicity","volume":"40","author":"Lee","year":"2008","journal-title":"Cancer Res. Treat."},{"issue":"1","key":"10.1016\/j.ctarc.2023.100750_bib0063","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s10741-017-9653-0","article-title":"Role of microRNAs in doxorubicin-induced cardiotoxicity: an overview of preclinical models and cancer patients","volume":"23","author":"Ruggeri","year":"2018","journal-title":"Heart Fail. Rev."},{"issue":"4","key":"10.1016\/j.ctarc.2023.100750_bib0064","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s00277-003-0615-3","article-title":"Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies","volume":"82","author":"Auner","year":"2003","journal-title":"Ann. Hematol."},{"issue":"1","key":"10.1016\/j.ctarc.2023.100750_bib0065","doi-asserted-by":"crossref","first-page":"27","DOI":"10.14712\/fb2010056010027","article-title":"MicroRNA MiR-1 Is up-regulated in remote myocardium in patients with myocardial infarction","volume":"56","author":"Bostjancic","year":"2010","journal-title":"Folia Biol. (Praha)"},{"issue":"10","key":"10.1016\/j.ctarc.2023.100750_bib0066","first-page":"4987","article-title":"Let-7f and MiRNA-126 correlate with reduced cardiotoxicity risk in triple-negative breast cancer patients who underwent neoadjuvant chemotherapy","volume":"11","author":"Zhu","year":"2018","journal-title":"Int. J. Clin. Exp. Pathol."},{"issue":"5","key":"10.1016\/j.ctarc.2023.100750_bib0067","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1093\/annonc\/mdi152","article-title":"CTnT can be a useful marker for early detection of anthracycline cardiotoxicity","volume":"16","author":"Kilickap","year":"2005","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.ctarc.2023.100750_bib0068","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004408","article-title":"Longitudinal assessment of vascular function with sunitinib in patients with metastatic renal cell carcinoma","volume":"11","author":"Catino","year":"2018","journal-title":"Circ. Heart Fail."},{"issue":"1","key":"10.1016\/j.ctarc.2023.100750_bib0069","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jchf.2012.09.001","article-title":"The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients","volume":"1","author":"Hall","year":"2013","journal-title":"JACC Heart Fail."},{"issue":"11","key":"10.1016\/j.ctarc.2023.100750_bib0070","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1093\/cvr\/cvaa195","article-title":"Non-coding RNAs: update on mechanisms and therapeutic targets from the ESC working groups of myocardial function and cellular biology of the heart","volume":"116","author":"B\u00e4r","year":"2020","journal-title":"Cardiovasc. Res."},{"issue":"42","key":"10.1016\/j.ctarc.2023.100750_bib0071","doi-asserted-by":"crossref","first-page":"4496","DOI":"10.1093\/eurheartj\/ehac337","article-title":"A circular RNA derived from the insulin receptor locus protects against doxorubicin-induced cardiotoxicity","volume":"43","author":"Lu","year":"2022","journal-title":"Eur. Heart J."},{"issue":"6","key":"10.1016\/j.ctarc.2023.100750_bib0072","doi-asserted-by":"crossref","first-page":"736","DOI":"10.3349\/ymj.2018.59.6.736","article-title":"Extracellular vesicles derived from hypoxic human mesenchymal stem cells attenuate GSK3\u03b2 expression via MiRNA-26a in an ischemia-reperfusion injury model","volume":"59","author":"Park","year":"2018","journal-title":"Yonsei Med. J."},{"issue":"3","key":"10.1016\/j.ctarc.2023.100750_bib0073","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1002\/jcb.27731","article-title":"Exosomes derived from MiR-146a-modified adipose-derived stem cells attenuate acute myocardial infarction-induced myocardial damage via downregulation of early growth response factor 1","volume":"120","author":"Pan","year":"2019","journal-title":"J Cell. Biochem."},{"issue":"9","key":"10.1016\/j.ctarc.2023.100750_bib0074","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/s41419-019-1901-x","article-title":"MiR-146a attenuates apoptosis and modulates autophagy by targeting TAF9b\/P53 pathway in doxorubicin-induced cardiotoxicity","volume":"10","author":"Pan","year":"2019","journal-title":"Cell Death Dis."},{"issue":"4","key":"10.1016\/j.ctarc.2023.100750_bib0075","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1007\/s12031-015-0539-0","article-title":"Buyang huanwu decoction (BYHWD) enhances angiogenic effect of mesenchymal stem cell by upregulating VEGF expression after focal cerebral ischemia","volume":"56","author":"Yang","year":"2015","journal-title":"J. Mol. Neurosci."},{"issue":"7","key":"10.1016\/j.ctarc.2023.100750_bib0076","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/cvr\/cvz040","article-title":"Mesenchymal stromal cell-derived exosomes attenuate myocardial ischaemia-reperfusion injury through MiR-182-regulated macrophage polarization","volume":"115","author":"Zhao","year":"2019","journal-title":"Cardiovasc. Res."},{"issue":"1","key":"10.1016\/j.ctarc.2023.100750_bib0077","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10557-021-07228-5","article-title":"The function and therapeutic potential of circular RNA in cardiovascular diseases","volume":"37","author":"Wang","year":"2023","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"2","key":"10.1016\/j.ctarc.2023.100750_bib0078","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/eurheartj\/ehaa898","article-title":"Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human phase 1b randomized, double-blind, placebo-controlled study","volume":"42","author":"T\u00e4ubel","year":"2021","journal-title":"Eur. Heart J."},{"issue":"6","key":"10.1016\/j.ctarc.2023.100750_bib0079","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.jshs.2020.12.003","article-title":"The epigenetic landscape of exercise in cardiac health and disease","volume":"10","author":"Wu","year":"2021","journal-title":"J. Sport Health Sci."},{"issue":"11","key":"10.1016\/j.ctarc.2023.100750_bib0080","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1152\/physiolgenomics.00145.2010","article-title":"MicroRNAs 29 are involved in the improvement of ventricular compliance promoted by aerobic exercise training in rats","volume":"43","author":"Soci","year":"2011","journal-title":"Physiol. Genomics"},{"issue":"4","key":"10.1016\/j.ctarc.2023.100750_bib0081","first-page":"65","article-title":"Long non-coding RNAs in cardiovascular diseases: potential function as biomarkers and therapeutic targets of exercise training","volume":"7","author":"Correia","year":"2021","journal-title":"Noncoding RNA"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294223000722?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294223000722?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:35:00Z","timestamp":1762842900000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294223000722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":81,"alternative-id":["S2468294223000722"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2023.100750","relation":{},"ISSN":["2468-2942"],"issn-type":[{"type":"print","value":"2468-2942"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-coding RNAs, cancer treatment and cardiotoxicity: A triad of new hope","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2023.100750","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100750"}}